Get the Stockscreener App
15.28
1.38%
-0.205
Adma Biologics Inc stock is traded at $15.28, with a volume of 2.17M.
It is down -1.38% in the last 24 hours and up +4.14% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
See More
Previous Close:
$15.48
Open:
$15.49
24h Volume:
2.17M
Relative Volume:
0.64
Market Cap:
$3.65B
Revenue:
$474.17M
Net Income/Loss:
$208.93M
P/E Ratio:
17.99
EPS:
0.8493
Net Cash Flow:
$65.61M
1W Performance:
-2.14%
1M Performance:
+4.14%
6M Performance:
-35.09%
1Y Performance:
-21.18%
1-Day Range:
$15.10
$15.68
1-Week Range:
$15.07
$15.76
52-Week Range:
$13.82
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
15.28 | 3.69B | 474.17M | 208.93M | 65.61M | 0.8493 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.63 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
640.13 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.19 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
823.88 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.89 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
Y Intercept Hong Kong Ltd Buys 38,809 Shares of ADMA Biologics Inc $ADMA - MarketBeat
Risk adjusted return profile for ADMA Biologics Inc. analyzedWatch List & High Accuracy Investment Entry Signals - newser.com
Applying Wyckoff theory to ADMA Biologics Inc. stockJuly 2025 Pullbacks & Safe Capital Growth Plans - newser.com
ADMA Biologics (ADMA): Evaluating Valuation After Major Institutional Exit by Palisades Investment Partners - Yahoo Finance
Can ADMA Biologics Inc. stock attract ESG capital inflowsGap Down & Real-Time Stock Entry Alerts - newser.com
ADMA Biologics (ADMA) to Release Quarterly Earnings on Thursday - MarketBeat
Will ADMA Biologics Inc. stock keep outperforming rivalsTreasury Yields & Weekly Hot Stock Watchlists - newser.com
ADMA Biologics Inc Stock Analysis and ForecastSector Performance Drivers & Free Take Advantage Of Momentum - earlytimes.in
Will ADMA Biologics Inc. stock continue dividend increasesTrade Risk Assessment & Daily Volume Surge Trade Alerts - newser.com
Building trade automation scripts for ADMA Biologics Inc.Trade Performance Summary & Weekly Top Stock Performers List - newser.com
ADMA Biologics Inc (ADMA) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It? - sharewise.com
ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025 - The Manila Times
ADMA Biologics (Nasdaq: ADMA) sets Nov. 5 call at 4:30 p.m. ET for third-quarter results - Stock Titan
Is ADMA Biologics Stock Trading At A Bargain? - Trefis
Signal Recap: Why ADMA Biologics Inc. stock is a must watch in 2025Earnings Performance Report & Verified Swing Trading Watchlist - fcp.pa.gov.br
Peregrine Capital Management LLC Acquires 53,515 Shares of ADMA Biologics Inc $ADMA - MarketBeat
Will ADMA Biologics Inc. stock outperform international peersExit Point & Risk Controlled Swing Trade Alerts - fcp.pa.gov.br
Risk Check: Why ADMA Biologics Inc. stock is a must watch in 2025 - Fundação Cultural do Pará
Analyst Upgrade: Will ADMA Biologics Inc. stock continue dividend increasesPortfolio Value Summary & Real-Time Volume Spike Alerts - fcp.pa.gov.br
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider - sharewise.com
ADMA Biologics Adjusts Valuation Amid Strong Financial Performance and Growth Metrics - Markets Mojo
Is ADMA Biologics Inc a good long term investmentEarnings Date Calendar & Low Entry Investment Ideas - earlytimes.in
ADMA Biologics (ADMA): Assessing Valuation After Q2 Earnings Miss and Upgraded Financial Outlook - Sahm
Comparing ADMA Biologics Inc. in custom built stock radarsTrade Exit Summary & Trade Opportunity Analysis - newser.com
Allianz Asset Management GmbH Buys 33,894 Shares of ADMA Biologics Inc $ADMA - MarketBeat
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):